New hope for brain metastases: drug combo targets hard-to-treat breast cancer
NCT ID NCT07136428
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This study tests a new drug, asciminib, combined with trastuzumab in 42 adults with HER2+ breast cancer that has spread to the brain. Participants must have tried at least one prior treatment, including T-DXd and tucatinib. The goal is to see if the combination can shrink brain tumors and control the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2+ METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University
RECRUITINGDurham, North Carolina, 27710, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.